VALN

Valneva SE ADR

VALN, USA

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; and IXCHIQ/ VLA1553, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus. The company also develops VLA15, a vaccine candidate against Borrelia, the bacterium that causes Lyme disease; S4V2, a tetravalent bioconjugate vaccine candidate against shigellosis, a diarrheal infection caused by Shigella bacteria; VLA1601, a vaccine candidate targeting the Zika virus, a mosquito-borne viral disease; VLA1554, a vaccine candidate targeting human metapneumovirus; VLA84, a vaccine candidate targeting the prevention of primary symptomatic clostridium difficile infection; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of Europe, and internationally. The company was founded in 1998 and is based in Saint-Herblain, France.

https://valneva.com

Stock Price

$0.00

0%

increase compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
VALN
stock
VALN

Valneva stock falls after withdrawing chikungunya vaccine BLA in U.S. By Investing.com Investing.com Nigeria

Read more →
VALN
stock
VALN

Is VALN stock attractive for passive investors - 2025 Momentum Check & Real-Time Buy Signal Alerts bollywoodhelpline.com

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

BUY

Target Price:

$12.8875

Analyst Picks

Strong Buy

2

Buy

1

Hold

1

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very High

5.65

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-29.48 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-9.90 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

-61.58 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Very Low

1.98

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 3.56% of the total shares of Valneva SE ADR

1.

Novo A/S

(2.766%)

since

2025/06/30

2.

General American Investors Co Inc

(0.4127%)

since

2025/06/30

3.

Wells Fargo & Co

(0.2855%)

since

2025/06/30

4.

Citadel Advisors Llc

(0.0416%)

since

2025/06/30

5.

Ironwood Investment Management LLC

(0.0293%)

since

2025/06/30

6.

Morgan Stanley - Brokerage Accounts

(0.0094%)

since

2025/06/30

7.

VSM Wealth Advisory, LLC

(0.0047%)

since

2025/06/30

8.

Fidelity Nasdaq Composite Index

(0.0034%)

since

2025/07/31

9.

Advisor Group Holdings, Inc.

(0.0022%)

since

2025/06/30

10.

GAMMA Investing LLC

(0.0016%)

since

2025/06/30

11.

Ridgewood Investments LLC

(0.0006%)

since

2025/06/30

12.

Rhumbline Advisers

(0.0001%)

since

2025/06/30

13.

Hanson Mcclain Inc

(0%)

since

2025/06/30

14.

UBS Group AG

(0%)

since

2025/06/30

15.

Activest Wealth Management

(0%)

since

2025/06/30

16.

ABC arbitrage SA

(0%)

since

2025/03/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

-0.3694

Latest Release

Date

2025-09-30

EPS Actual

-0.5605

EPS Estimate

-0.333

EPS Difference

-0.2275

Surprise Percent

-68.3183%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Weak Deep Value(2)
Defensive
Moderately Defensive(5.5)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(3.8)
GARP
Not Attractive for GARP(1.5)
Growth
Weak Growth Prospect(1)
Momentum
Moderate Momentum(3.5)
Net Net
Not Undervalued (Net-Net)(1.5)
Quality
Low Quality Business(1.5)
Value
Fair Value(3.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.